Document:

EX-10.8.2

 Exhibit 10.8.2 

NON-COMPETITION AND NON-SOLICITATION OF CUSTOMER AGREEMENT 

THIS NON-COMPETITION AGREEMENT (“Agreement”) is made by and between Capital One Financial Corporation, a Delaware corporation, on its own behalf and
on behalf of its affiliates and subsidiaries (collectively, “Capital One”) and Jonathan W. Witter, an individual residing
at                                        
                                      (“You”), and
effective as of this __th day of September, 2010 (“Effective Date”). In consideration of the mutual promises between the parties in this Agreement, and in consideration of Your continued employment thereafter, which You acknowledge to be
good and sufficient consideration, it is agreed as follows: 
 1. Covenant Not to Compete. 

a. Legitimate Business Interest. You acknowledge and agree that Capital One has multiple legitimate business interests in
protecting its Confidential Information and Trade Secrets, as well as its customer and other business relationships, and that the 1 Year Non-Competition Covenant set forth in Paragraph 1(c) and 2 Year Non-Competition Covenant set forth in Paragraph
1(d) are narrowly tailored to protect Capital One’s legitimate business interests. “Confidential Information” means information, knowledge, data, specialized training, or other information that derives actual or potential value from
the fact that it is not generally known to members of the general public, which concerns the business or affairs of Capital One or Capital One’s customers. “Trade Secret” means information, including but not limited to, a model,
formula, pattern, compilation, program, device, method, technique, or process, that: (a) derives independent economic value, actual or potential, from not being generally known to, and not being readily ascertainable by proper means by, other
persons who can obtain economic value from its disclosure or use, and (b) is the subject of efforts that are reasonable under the circumstances to maintain its secrecy. You acknowledge and agree that Capital One has taken reasonable measures to
preserve the secrecy of its Confidential Information and Trade Secrets. 
 b. Access and Exposure to Confidential Information.
During Your employment, and further in consideration for the 1 Year Non-Competition Covenant and 2 Year Non-Competition Covenants set forth in Paragraphs 1(c) and 1(d), respectively, Capital One has provided or will provide You with Trade Secrets
and other Confidential Information regarding Capital One’s operations, methods, plans and/or strategies. 
 c. 1 Year
Non-Competition Covenant. For one (1) year following Your Termination Date (the “1 Year Non-Competition Period”), You shall not, within the 1 Year Restricted Area (defined below), provide Retail Branch Banking Services to or
on behalf of any entity. “Termination Date” means the date on which Your employment with Capital One ends, whether voluntarily or involuntarily. “Retail Branch Banking Services” means banking services provided via a branch
banking network directly to and/or on behalf of individual customers. The 1 Year Restricted Area shall mean the states containing at least one Capital One Bank branch as of Your Termination Date. 

d. 2 Year Non-Competition Covenant. For two (2) years following Your Termination Date (the “2 Year Non-Competition
Period”), You shall not, within the 2 Year Restricted Area (defined below), provide to any entity services (i) that are the same as or substantially similar to those You performed for Capital One during the twenty four (24) month
period prior to Your Termination Date (the “Look-Back Period”), and (ii) that compete with any business for which You performed such services during the Look-Back Period. For the avoidance of doubt, this 2 Year Non-Competition
Covenant does not apply to Retail Branch Banking Services. Provided You performed such services during the Look-Back Period, services subject to this 2 Year Non-Competition Covenant would include, without limitation, national direct bank, credit
card, debit card, automotive lending, mortgage lending, and installment loan services. The restrictions of this 2 Year Non-Competition Covenant apply to all activity performed throughout the United States (the “2 Year Restricted Area”),
other than Retail Branch Banking Services, defined above. You acknowledge and agree that, in light of Capital One’s nation-wide business activities, and Your work on such nation-wide activities, this geographic scope is narrowly tailored to
protect Capital One’s legitimate business interests. 
 2. Covenant Not to Solicit Customers. For a period of two
(2) years following Your Termination Date, You shall not, within the 2 Year Non-Competition Covenant, directly or indirectly solicit, encourage, or induce any Capital One customer to sever, terminate or transfer their account or relationship
with Capital One to any other entity. This Paragraph 2 applies to any Capital One customer (a) with whom You had personal contact, or (b) about whom You learned Confidential Information during Your employment at Capital One. 

 3. Payments during the 1 Year Non-Competition Period and 2 Year Non-Competition
Period. 
 a. Calculation of Incentive Payment. Subject to Paragraphs 3(b), 9, and 11, and in consideration for
the 1 Year Non-Competition Covenant and 2 Year Non-Competition Covenant set forth in Paragraph 1(c) and 1(d) of this Agreement, Capital One shall (i) pay You Your base salary then in effect at the time of Your Termination Date for the length of
the 2 Year Non-Competition Period (the “Incentive Payment”), and (ii) reimburse You for the employer portion of Your health care premium payments, along with the 2% administrative fee for continued health insurance coverage under the
Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”), at the level of coverage in effect at your Termination Date for a period not to exceed eighteen (18) months from your Termination Date (collectively the “Incentive
Payment”). You will not be eligible for these health insurance premium payments if you fail to enroll in COBRA or if you become eligible to receive, or begin receiving, health care coverage from another employer or party. If Your employment is
terminated for any reason other than Your death, Disability or for Cause, one-half of the Incentive Payment (but in no event more than the amount specified in Treasury Regulation section 1.409A-1(b)(9)(iii)(A) as of the Termination Date) shall be
paid to You in a lump sum within 30 days following Your Termination Date, and the balance of the Incentive Payment shall be paid to You in a lump sum within 30 days following the second anniversary of Your Termination Date. Capital One reserves the
right to withhold from such amounts all applicable international, federal, state and local taxes. 
 b. Criteria for Incentive
Payment. Except as provided in Paragraphs 9 and 11, and subject to this Paragraph 3(b), if Your employment is terminated by Capital One for any reason other than Your death, Disability or for Cause, You shall receive an Incentive Payment.
Your receipt of an Incentive Payment is expressly conditioned on Your full compliance with all of the terms of this Agreement. If, and to the extent that, You otherwise are entitled to receive any severance-type payments during the 1 Year
Non-Competition Period and/or 2 Year Non-Competition Period under any separate plan, arrangement or agreement (such as an employment agreement or a severance plan, arrangement or agreement) then to the extent provided for under such plan,
arrangement or agreement, the Incentive Payments under this Agreement shall offset amounts payable under such separate plan, arrangement or agreement. “Cause” means (i) a material breach of any of the provisions of this Agreement;
(ii) willful and serious misconduct in the performance of Your duties including, without limitation, theft, falsification of documents, mistreatment of other employees, violence, drug or alcohol abuse in the workplace, conduct that violates
Capital One’s policies against discrimination and/or harassment, and serious acts of insubordination; (iii) a material or repeated violation of any code of conduct, business, compliance, or risk policy or standard of ethics generally
applicable to all associates or to associates of Your level at Capital One; (iv) failure to substantially perform Your duties as an employee of Capital One (other than as a result of physical or mental illness or injury), and Your continued
failure to substantially perform, as determined by Capital One, for at least fifteen (15) days after written demand from Capital One for substantial performance that specifically identifies the manner in which Capital One expects You to improve
Your performance; or (v) conviction of a felony, or other serious crime involving moral turpitude or breaches of the duties of honesty, fiduciary duty, and/or good faith. “Disability” means Your inability to perform the essential
functions of Your position due to a medically determinable physical or mental impairment which continues for a period of at least 6 consecutive months or for more than 120 days out of any consecutive 360 day period. 

c. Voluntary Termination for Good Reason. If You terminate Your employment voluntarily for Good Reason (as defined in your Offer
Letter), then Capital One may elect to waive or enforce your 1 Year Non-Competition Covenant and 2 Year Non-Competition Covenant in Paragraphs 1(c) and 1(d) of this Agreement (collectively, “Non-Competition Covenants”). Capital One’s
decision to waive or enforce Your Non-Competition Covenants shall be in its sole discretion. If Capital One elects to enforce Your Non-Competition Covenants, You shall be paid the Incentive Payment in the manner set forth in Section 3(b) of
this Agreement. If Capital One elects to waive Your Non-Competition Covenants, You shall not be eligible for the Incentive Payment in Paragraph 3(b), and you will no longer be bound by such Non-Competition Covenants. For the avoidance of doubt, any
potential or actual waiver of Your Non-Competition Covenants will in no way impact your other obligations to Capital One including, without limitation, the Covenant Not to Solicit Customers Paragraph 2 of this Agreement, as well as your obligations
regarding Confidential Information, Ownership of Work Product, and Non-Solicitation of Employees set forth in your Confidentiality, Work Product, and Non-Solicitation of Employee Agreement (“CWP+NS”) and other similar agreements. 

 d. Section 409A. Notwithstanding any other provision of this Agreement to the
contrary, Incentive Payments, pursuant to this Paragraph 3, to the extent of payments made from Your Termination Date through March 15 of the calendar year following such Termination Date, are intended to constitute separate payments for
purposes of Section 1.409A-2(b)(2) of the Treasury Regulations and thus are payable pursuant to the “short-term deferral” rule set forth in Section 1.409A-1(b)(4) of the Treasury Regulations. To the extent such severance payments
are made following said March 15, they are intended to constitute separate payments for purposes of Section 1.409A-1(b)(9)(iii) of the Treasury Regulations to the maximum extent permitted by said provision, with any excess amount being
regarded as subject to the distribution requirements of Section 409A(a)(2)(A) of the Internal Revenue Code, including, without limitation, the requirement of Section 409A(a)(2)(B)(i) of the Code that payment be delayed until six
(6) months after separation from service if You are a “specified employee” within the meaning of the aforesaid section of the Code at the time of such separation from service. 

4. Consideration. As additional consideration for executing this Agreement, You shall receive one thousand dollars
($1000.00), less applicable tax withholdings, which amount shall be paid as soon as practicable after You return a signed copy of this Agreement to Capital One. 

5. Confidentiality. You agree that the fact, terms and conditions of this Agreement are strictly confidential, and with the
exception of Your counsel, Your spouse, and tax advisors, or except to the extent required by an order of a court having jurisdiction or under subpoena from an appropriate government agency (in which event, You will notify Capital One in writing of
the receipt of such subpoena or order prior to responding to any such order or subpoena), shall not be disclosed to any other person, entities or organizations, whether or not employed by Capital One. You further agree that in the event You share
the fact, terms or conditions of this Agreement or other Confidential Information with such authorized person(s) under this paragraph, You will instruct such person(s) to keep the information confidential pursuant to Your obligation to maintain the
confidentiality of such information. In addition, You agree not to use or disclose to any other person, including without limitation, future employers, any confidential or proprietary information or materials acquired in connection with Your
employment with Capital One (other than in the ordinary course of business on Capital One’s benefit) without the express written consent of Capital One, including without limitation, information and materials which identify or concern past,
present or future customers, businesses or plans, or constitute, embody or relate to research, development, financial accounting, programming and systems, inventions, databases, product designs, product implementations, modeling techniques, models
testing, test results, customer lists, marketing strategies, business plans, existing or potential new lines of business, credit policies and practices, accounts of customers or associates of Capital One or any other information or materials made or
furnished by Capital One or its affiliates (collectively “Confidential Information”). Confidential Information may be written, oral, recorded on tape or in any other media, and includes without limitation, information embodied in
documents, drawings, graphs, charts, presentations, recordings, microfiche, tapes, computer programs and other data compilations. Additionally, unless Capital One advises you to the contrary in writing, Confidential Information shall include all
software, hardware and other non-public information supplied to Capital One by third parties which is used by Capital One in its business. This confidentiality obligation shall be in addition to any other confidentiality agreements contained in any
applicable Confidentiality, Work Product and Non-Solicitation of Employee Agreement (“CWP+NS”) or other document signed by You, as well as continuing confidentiality obligations under the Capital One Code of Business Conduct and Ethics and
at common law. Notwithstanding the foregoing, You are permitted to disclose to prospective employers during the 1 Year Non-Competition Period and/or the 2 Year Non-Competition Period a redacted Agreement containing only Paragraphs 1 and 2 of this
Agreement for the sole purpose of assessing Your non-competition and non-solicitation of customer obligations, respectively. 
 6.
Compliance Information and Review. During the 1 Year Non-Competition Period and 2 Year Non-Competition Period, You agree to notify Capital One in writing of the identity of any prospective employer or business opportunity on whose behalf
You intend to perform services during either the 1 Year Non-Competition Period or 2 Year Non-Competition Period, together with a brief description of Your intended functions, prior to accepting such employment or business opportunity. From time to
time during the 1 Year Non-Competition Period or 2 Year Non-Competition Period, Capital One may also request information from You to permit it to determine whether You are otherwise in compliance with this Agreement. You agree to provide timely,
complete and accurate information responsive to all such requests within five (5) business days after receiving such a request. You also hereby authorize Capital One to contact Your future employers and other persons and entities with whom You
engage in any business relationship during the 1 Year Non-Competition Period or 2 Year Non-Competition Period to confirm Your compliance with this Agreement, or to communicate Your obligations under this Agreement. 

 7. Reasonableness. You acknowledge that the restrictions set forth in this
Agreement are necessary and reasonable to protect Capital One’s legitimate business interests, most notably safeguarding its Confidential Information and Trade Secrets, and protecting its business relationships. You agree that, if Your
employment with Capital One terminates, You will be able to earn a livelihood without violating this Agreement, including, without limitation, the 1 Year Non-Competition Covenant and/or 2 Year Non-Competition Covenant set forth in Paragraphs 1(c)
and 1(d), respectively. 
 8. Irreparable Harm; Injunctive Relief. You acknowledge and agree that Your violation of any
provision of this Agreement will cause immediate, substantial and irreparable harm to Capital One which cannot be adequately redressed by monetary damages alone. In the event of Your violation or threatened violation of any provision of this
Agreement, You agree that Capital One, without limiting any other legal or equitable remedies available to it, shall be entitled to equitable relief, including, without limitation, temporary, preliminary and permanent injunctive relief, return of
property, and specific performance, from any court of competent jurisdiction, as provided in Paragraph 13. 
 9. Repayment of
Consideration; Attorneys’ Fees and Costs. If You assert in any legal proceeding that this Agreement is not enforceable or if You breach Your obligations under this Agreement, You shall (i) thereby void Capital One’s
obligations to You for any Incentive Payments, (ii) immediately forfeit or repay all amounts of the Incentive Payments paid to You by Capital One, and (iii) pay all reasonable costs and attorneys’ fees incurred by Capital One in such
legal proceeding, in addition to any other damages or relief to which Capital One may be entitled. Capital One shall pay all reasonable costs and attorneys’ fees incurred by You if You obtain a judgment against Capital One in an action brought
by You to enforce the terms of this Agreement against Capital One. For the avoidance of doubt, Capital One shall not pay any costs and/or attorney’s fees if You assert in any legal proceeding that this Agreement is not enforceable, or if You
breach Your obligations under this Agreement. 
 10. Employment At Will. You and Capital One acknowledge that You are, or will
be, employed by Capital One as an “at will” employee. Nothing in this Agreement shall be construed to create a contract of employment or modify Your employment “at will” status. 

11. Court’s Right to Modify Restriction. The parties agree that if at the time enforcement is sought, a court of competent
jurisdiction adjudges any terms of any provision of this Agreement to be void, invalid, or unenforceable, including without limitation portions of the 1 Year Non-Competition Covenant or 2 Year Non-Competition Covenant contained in Paragraphs 1(c)
and 1(d) above, such court may modify or reform such provision so that it is enforceable to the fullest extent permitted by applicable law, or if such modification or reformation is not possible, shall sever the unenforceable portion of the
provision, and enforce the remaining provisions of the Agreement, which shall remain in full force and effect. If a court of competent jurisdiction determines that the 1 Year Non-Competition Covenant and/or 2 Year Non-Competition Covenant is void,
invalid, or unenforceable, or if it amends or severs it, Capital One shall have no obligation to make the Incentive Payment described in Paragraph 3(a) during any period in which the court determines that the 1 Year Non-Competition Covenant and/or 2
Year Non-Competition Covenant shall not be in full effect. 
 12. Successors and Assigns. The rights and obligations under
this Agreement are personal to You and cannot be assigned to any party. This Agreement and all promises made herein shall survive the execution of this Agreement and shall be binding upon and inure to the benefit of Capital One’s successors and
assigns without further consent. 
 13. Choice of Law. This Agreement shall be governed by and construed in accordance with
the laws of the headquarters of Capital One, the Commonwealth of Virginia, without regard to its principles of conflicts of law. 
 14.
Personal Jurisdiction/Venue. Capital One and You hereby consent and submit to the personal jurisdiction and venue of any state or federal court located in any city or county where Capital One has offices within the Commonwealth of
Virginia for resolution of any and all claims, causes of action or disputes arising out of or related to this Agreement. 

 15. Entire Agreement; Integration. This Agreement does not supersede, but rather
supplements, any written policies of Capital One generally applicable to employees of Capital One respecting the treatment of Confidential Information and Work Product and any Change of Control Employment Agreement or other severance plan,
arrangement or agreement applicable to You. This Agreement may be modified only by a writing signed by the party to be bound. 
 16.
Notices. All requests, notices and other communications required or permitted to be given under this Agreement shall be in writing. Delivery thereof shall be deemed to have been made when such notice shall have been either (i) duly
mailed by first-class mail, postage prepaid, return receipt requested, or any comparable or superior postal or air courier service then in effect, or (ii) transmitted by hand delivery, telegram, telex, telecopier or facsimile transmission, to
the party entitled to receive the same at the address indicated below or at such other address as such party shall have specified by written notice to the other party hereto given in accordance herewith or, if You are still employed by Capital One,
at Your interoffice address or electronic mail address at Capital One: 
 If to You: 

Jonathan W. Witter 

[To the most recent address on record with Capital One] 

If to Capital One: 

Non-Competition Program Administrator 

Capital One Financial Corporation 

15000 Capital One Drive 

Richmond, Virginia 23238 

17. Headings. The headings in this Agreement are included for convenience only and shall not constitute a part of the Agreement
nor shall they affect its meaning, construction or effect. 
 18. Consultation with Counsel. You are advised and encouraged to
consult with independent legal counsel before executing this Agreement. 
 THE PARTIES have read this Agreement, understand it, and accept
all of its terms: 
  

					
	Employee	 		 	Capital One Financial Corporation
			
	/s/ Jonathan W. Witter	 		 	/s/ Jory Berson
	Signature	 		 	Signature
			
	Jonathan W. Witter	 		 	Chief Human Resources ExecutiveEX-4.1

 Exhibit 4.1 

COMMON STOCK PURCHASE WARRANT 

SERIES A 
 CUSIP 867328
114 
 SUNESIS PHARMACEUTICALS, INC. 
  

					
	 Warrant Shares:  [*]
	  	 	Issue Date:                 , 2014	  

 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value
received,            (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions set forth herein, at any time on or after the
Unblinding Date (as defined below) and until 5:00 p.m., New York time, on the later of (i) December 4, 2014 and (ii) the date thirty (30) days following the Unblinding Date but in no event no later than March 4, 2016 (the
“Expiration Date”) but not thereafter, to subscribe for and purchase from Sunesis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), up to [*] shares (the “Warrant Shares”) of the
Company’s common stock, par value $0.0001 per share (“Common Stock”). For purposes of this Warrant, the “Unblinding Date” shall mean the date on which data from the Company’s VALOR trial, a Phase 3 pivotal
clinical trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia, that is unblinded by the independent Data and Safety Monitoring Board overseeing such clinical trial, is first publicly
announced in a press release issued by the Company. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). 

Section 1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that
certain Warrant Agency Agreement between the Company and American Stock Transfer & Trust Company, LLC (the “Warrant Agent”), dated as of February [—], 2014 (the
“Warrant Agency Agreement”). The following additional terms shall have the following meanings: 
 a)
“Trading Day” shall mean any day on which the Common Stock is traded on the Trading Market. 
 b) “Trading
Market” shall mean the principal securities exchange or securities market, including an over-the-counter market, on which the Common Stock is then traded in the United States. 

Section 2. Exercise. This Warrant may be exercised by the Holder only if a registration statement registering the
issuance of the Warrant Shares under the Securities Act of 1933, as amended (the “Securities Act”), is effective and available for the issuance of the Warrant Shares. 

a) Exercise of Warrant. Subject to the foregoing limitation on exercise, the purchase rights represented by this Warrant
may be exercised, in whole or in part, at any time or times on or after the Unblinding Date and on or before the Expiration Date by delivery (whether via facsimile or otherwise) to the Company (or the Warrant Agent or such other office or agency of
the Company as it may designate by notice in writing to the registered Holder at the address of the Holder appearing on the books of the Company or the Warrant Agent) of a duly executed copy of the Notice of Exercise form annexed hereto and by
payment to the Warrant Agent of an amount equal to the aggregate Exercise Price of the Warrant Shares thereby purchased by wire transfer. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of
guarantee or notarization) of any Notice of Exercise form be required. The Holder shall not be required to physically surrender this Warrant to the Company or the Warrant Agent until the Holder has purchased all of the Warrant Shares available
hereunder and the Warrant has been exercised in full, in which case the Holder shall surrender this Warrant to the Company or the Warrant Agent for cancellation within three (3) Trading Days after the date the final Notice of Exercise is
delivered to the Company or the Warrant Agent. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares
purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company or the Warrant Agent shall maintain records showing the number of Warrant Shares purchased and the date of such purchases.
The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for
purchase hereunder at any given time may be less than the amount stated on the face hereof.  
 b) Exercise Price.
The exercise price per share of Common Stock under this Warrant shall be $8.50, subject to adjustment as provided herein (the “Exercise Price”). 

  
 1. 

 c) Mechanics of Exercise. 

i. Delivery of Certificates Upon Exercise. Certificates for shares purchased hereunder shall be transmitted by the Warrant Agent to the
Holder by crediting the account of the Holder’s prime broker with The Depository Trust Company (“DTC”) through its Deposit/Withdrawal at Custodian (“DWAC”) system if the Company is then a participant in such
system and otherwise by physical delivery to the address specified by the Holder in the Notice of Exercise by the date that is three (3) Trading Days after the receipt by the Warrant Agent of the Notice of Exercise (provided that payment of the
Exercise Price has then been received by the Warrant Agent) (such date, the “Warrant Share Delivery Date”). This Warrant shall be deemed to have been exercised upon proper delivery of the Notice of Exercise and payment of the
Exercise Price. The Warrant Shares shall be deemed to have been issued, and the Holder or any other person so designated to be named therein shall be deemed to have become a holder of record of such shares for all purposes, as of the date the
Warrant has been exercised. 
 ii. Delivery of New Warrant Upon Exercise. If this Warrant shall have been exercised in part, the
Company shall (or shall direct the Warrant Agent to), at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the certificate or certificates representing Warrant Shares, deliver to the Holder a new
Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant. 

iii. Rescission Rights. If the Company fails to cause the Warrant Agent to transmit to the Holder a certificate or the certificates
representing the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then, the Holder will have the right to rescind such exercise. 

iv. No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of
this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall (or shall direct the Warrant Agent to), at its election, either pay a cash adjustment in respect of such final
fraction in an amount equal to such fraction multiplied by the Exercise Price or round (up or down) to the nearest whole share. 
 v.
Charges, Taxes and Expenses. Issuance of certificates for Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes
and expenses shall be paid by the Company, and such certificates shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that in the event certificates for Warrant Shares
are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company or the Warrant Agent may require, as a
condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. 
 vi. Closing of Books.
The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant pursuant to the terms hereof. 

d) Holder’s Exercise Limitations. Notwithstanding anything to the contrary contained in this Warrant, this Warrant shall not be
exercisable by the Holder hereof to the extent (but only to the extent) that the Holder or any of its Affiliates would beneficially own in excess of 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the
issuance of shares of Common Stock issuable upon exercise of this Warrant (the “Maximum Percentage”). The Holder, upon not less than 61 days’ prior notice to the Company, may increase or decrease the Maximum Percentage
provisions of this Section 2(d), provided that the Maximum Percentage in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of
this Warrant held by the Holder and the provisions of this Section 2(d) shall continue to apply. Any such increase or decrease will not be effective until the 61st day after such notice is
delivered to the Company. For purposes of this Section 2(d), the number of shares of Common Stock beneficially owned by the Holder and its Affiliates shall include the number of Warrant Shares which are subject to the Notice of Exercise with
respect to which such determination is being made, but shall exclude the number of shares of Common Stock which are issuable upon (i) exercise of the remaining, unexercised portion of this Warrant and beneficially owned by the Holder or any of
its Affiliates, and (ii) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company beneficially owned by the Holder or any of its Affiliates that are subject to a limitation on conversion or
exercise similar to the limitation contained herein. To the extent the above limitation applies, the determination of whether this Warrant shall be exercisable (vis-à-vis other convertible, exercisable or exchangeable securities owned by the
Holder or any of its Affiliates) and of which such securities shall be exercisable (as among all such securities owned by the 

  
 2. 

 
Holder) shall, subject to such Maximum Percentage limitation, be determined by the Holder, and the Company shall have no responsibility for determining the accuracy of the Holder’s
determination. No prior inability to exercise this Warrant pursuant to this paragraph shall have any effect on the applicability of the provisions of this paragraph with respect to any subsequent determination of exercisability. For the purposes of
this paragraph, beneficial ownership and all determinations and calculations (including, without limitation, with respect to calculations of percentage ownership) shall be determined in accordance with Section 13(d) of the Exchange Act and the
rules and regulations promulgated thereunder. The provisions of this paragraph shall be implemented in a manner otherwise than in strict conformity with the terms of this paragraph to correct this paragraph (or any portion hereof) which may be
defective or inconsistent with the intended Maximum Percentage beneficial ownership limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such Maximum Percentage limitation. The limitations
contained in this paragraph shall apply to a successor Holder of this Warrant. The holders of Common Stock shall be third party beneficiaries of this paragraph and the Company may not waive this paragraph without the consent of holders of a majority
of its outstanding Common Stock. For any reason at any time, upon the written or oral request of the Holder, the Company shall within one (1) Business Day confirm orally and in writing to the Holder the number of shares of Common Stock then
outstanding, including by virtue of any prior conversion or exercise of convertible or exercisable securities into Common Stock, including, without limitation, pursuant to this Warrant. 

Section 3. Certain Adjustments. 

a) Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or
otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued
by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller
number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company (collectively with the actions described in (i), (ii), (iii) and (iv), a “Share
Reorganization”), then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and
of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price
of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall
become effective immediately after the effective date in the case of a subdivision, combination or re-classification, but if the Company shall legally abandon any such dividend, distribution, subdivision, combination or reclassification prior to
effecting such action, no adjustment shall be made pursuant to this Section 3(a) in respect of such action. 
 b) Pro Rata
Distributions. If the Company, at any time while this Warrant is outstanding, shall distribute to all holders of Common Stock (and not to the Holders) evidences of its indebtedness or assets (including cash and cash dividends) or rights or
warrants to subscribe for or purchase any security other than a Share Reorganization, then, in each such case, the Exercise Price shall be adjusted by multiplying the Exercise Price in effect immediately prior to the record date fixed for
determination of stockholders entitled to receive such distribution by a fraction of which the denominator shall be the VWAP (as defined below) determined as of the record date, and of which the numerator shall be such VWAP on such record date less
the then per share fair market value at such record date of the portion of such assets or evidence of indebtedness so distributed applicable to one outstanding share of the Common Stock as determined by the Board of Directors in good faith; provided
that in no event shall the Exercise Price be increased as a result of the application of this Section 3(b). Simultaneously with any adjustment to the Exercise Price pursuant to this Section 3(b), the number of Warrant Shares that may be
purchased upon exercise of this Warrant shall be increased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder for the adjusted number of Warrant Shares shall be the same as the aggregate Exercise Price in
effect immediately prior to such adjustment (without regard to any limitations on exercise contained herein). In either case the adjustments shall be described in a statement provided to the Holder of the portion of assets or evidences of
indebtedness so distributed or such subscription rights applicable to one share of Common Stock. Such adjustments shall be made whenever any such distribution is made and shall become effective immediately after the record date mentioned above, but
if the Company shall legally abandon any such distribution prior to effecting such distribution, no adjustments shall be made pursuant to this Section 3(b) in respect of such action. 

For purposes of this Section 3(b), “VWAP” means, for any date, the price determined by the first of the following
clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common
Stock is then 

  
 3. 

 
listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time), (b) if the OTC Bulletin Board is not a Trading
Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the OTC Bulletin Board, (c) if the Common Stock is not then listed or quoted for trading on the OTC Bulletin Board and if prices for
the Common Stock are then reported in the “Pink Sheets” published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so
reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably
acceptable to the Company, the fees and expenses of which shall be paid by the Company. 
 c) Fundamental Transaction. If, at any
time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation with or into another Person, (ii) the Company, directly or indirectly, effects any
sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer
(whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of
the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which
the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other
business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than 50% of the outstanding shares of Common Stock (not including
any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a
“Fundamental Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence
of such Fundamental Transaction (without regard to any limitation in Section 2(d) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving
corporation, and any additional consideration (together, the “Alternate Consideration”), if any, receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is
exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(d) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately
adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate
Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental
Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Any such payment of such amount of such Alternative Consideration
shall be made in the same form of consideration (whether securities, cash or property) as is given to the holders of Common Stock in such Fundamental Transaction, and if multiple forms of consideration are given, the consideration shall be paid to
the Holder in the same proportion as such consideration is paid to the holders of Common Stock. The terms of any agreement pursuant to which a Fundamental Transaction is effected shall include terms requiring any such successor or surviving entity
to comply with the provisions of this Section 3(c) and insuring that this Warrant (or any such replacement security) will be similarly adjusted upon any subsequent Fundamental Transaction. 

d) Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest whole share, as the case
may be. For purposes of this Section 3, any calculation of the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall not include treasury shares, if any. Notwithstanding anything to the contrary in this
Section 3, no adjustment in the Exercise Price shall be required unless such adjustment would require an increase or decrease of at least 1% in such price; provided however, that any adjustments which by reason of the immediately
preceding sentence are not required to be made shall be carried forward and taken into account in any subsequent adjustment. In any case in which this Section 3 shall require that an adjustment in the Exercise Price be made effective as of a
record date for a specified event, if Holder exercises this Warrant after such record date, the Company may elect to defer, until the occurrence of such event, the issuance of the shares of Common Stock and other capital stock of the Company in
excess of the shares of Common Stock and other capital stock of the Company, if any, issuable upon such exercise on the basis of the Exercise Price in effect prior to such adjustment; provided, however, that in such case the Company or
the Warrant Agent shall deliver to the Holder a due bill or other appropriate instrument evidencing the Holder’s right to receive such additional shares and/or other capital securities upon the occurrence of the event requiring such adjustment.

  
 4. 

 e) Par Value. Notwithstanding anything to the contrary in this Warrant, in no event shall
the Exercise Price be reduced below the par value of the Company’s Common Stock. 
 Section 4. Transfer of Warrant. 

a) Transferability. Subject to compliance with any applicable securities laws, this Warrant and all rights hereunder (including,
without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or the Warrant Agent (or other designated agent), together with a written assignment of this
Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the
Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant
evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new
Warrant issued. 
 b) New Warrants. Subject to and in accordance with Section 6 the Warrant Agency Agreement, this Warrant may
be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company or the Warrant Agent (or other designated agent), together with a written notice specifying the names and denominations in which new Warrants
are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver (or cause the Warrant
Agent to deliver) a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date set forth on the
first page of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto. 

c) Warrant Register. This Warrant shall be issuable in book entry form (the “Book-Entry Warrant Certificate”) and
shall initially be represented by one or more Book-Entry Warrant Certificates deposited with The Depository Trust Company (“DTC”) and registered in the name of Cede & Co., a nominee of DTC, or as otherwise directed by DTC.
Ownership of beneficial interests in this Warrant shall be shown on, and the transfer of such ownership shall be effected through, records maintained by (i) DTC or its nominee for each Book-Entry Warrant Certificate or (ii) institutions
that have accounts with DTC (the “Warrant Register”). If DTC subsequently ceases to make its book-entry settlement system available for this Warrant, the Company may instruct the Warrant Agent regarding other arrangements for
book-entry settlement. In the event that this Warrant is not eligible for, or it is no longer necessary to have this Warrant available in, book-entry form, the Warrant Agent shall provide written instructions to DTC to deliver to the Warrant Agent
for cancellation each Book-Entry Warrant Certificate, and the Company shall cause the Warrant Agent to deliver to the Holder a physical certificate in the form of this Warrant and the Company or the Warrant Agent shall, thereafter, register this
Warrant, upon records to be maintained by the Company for that purpose, in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of
any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary. 
 Section 5.
Miscellaneous. 
 a) No Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(c)(i). 
 b) Loss,
Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company or the Warrant Agent of evidence reasonably satisfactory to them of the loss, theft, destruction or mutilation of this Warrant or any stock
certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it, and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will
make and deliver (or cause the Warrant Agent to deliver) a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate. 

c) Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day. 

d) Authorized Shares. The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and
unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon 

  
 5. 

 
the exercise of any purchase rights under this Warrant (without regard to any limitations on exercise contained herein). The Company further covenants that its issuance of this Warrant shall
constitute full authority to its officers who are charged with the duty of executing stock certificates to execute and issue the necessary certificates for the Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company
will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common
Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such
Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer
occurring contemporaneously with such issue). 
 e) No Impairment. Except and to the extent as waived or consented to by the Holder,
the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary
action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or
appropriate to protect the rights of the Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable
therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon
the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to
perform its obligations under this Warrant. 
 f) Governing Law. This Warrant shall be governed by, and construed in accordance with,
the laws of the State of New York without giving effect to the conflicts of law principles thereof. 
 g) Nonwaiver and Expenses. No
course of dealing or any delay or failure to exercise any right hereunder on the part of the Holder shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting any other provision of
this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs
and expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or
remedies hereunder. 
 h) Notices. 

i. Notice Procedures. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company
shall be delivered in accordance with the notice provisions of the Warrant Agency Agreement. 
 ii. Adjustment to Exercise Price.
Whenever the Exercise Price or number of Warrant Shares is adjusted pursuant to any provision of Section 3, the Company shall (or cause the Warrant Agent to) promptly provide the Holder a notice setting forth the Exercise Price and number of
Warrant Shares after such adjustment and setting forth a brief statement of the facts requiring such adjustment. 
 iii. Notice of Certain
Events. The Company shall (or shall cause the Warrant Agent to) promptly provide the Holder a notice of occurrence of the Unblinding Date, which notice may be satisfied by issuance of a public press release by the Company containing such
requisite information. 
 iv. Notice to Allow Exercise by the Holder. After the Unblinding Date and on or prior to the Expiration
Date, if (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be
required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange
whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company
shall cause to be mailed to the Holder at its last address as it shall appear upon the Warrant Register, at least ten (10) calendar days prior to the applicable record or effective date 

  
 6. 

 
hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to
be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger,
sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or
other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to mail such notice or any defect therein or in the mailing thereof shall not affect the validity of the
corporate action required to be specified in such notice. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may
otherwise be expressly set forth herein. 
 i) Limitation of Liability. No provision hereof, in the absence of any affirmative action
by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of
the Company, whether such liability is asserted by the Company or by creditors of the Company. 
 j) Remedies. The Holder, in
addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation
for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate. 

k) Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of the Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time
of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares. 
 l) Amendment. This Warrant may be modified or
amended or the provisions hereof waived with the written consent of the Company and the Holder. 
 m) Severability. Wherever
possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be
ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant. 

n) Confidentiality. The Holder agrees to keep confidential any proprietary information relating to the Company delivered by the Company
or the Warrant Agent hereunder; provided that nothing herein shall prevent the Holder from disclosing such information: (i) to any holder of Warrants or Warrant Shares, (ii) to any Affiliate of any holder of Warrants or Warrant Shares or
any actual or potential transferee of the rights or obligations hereunder that agrees to be bound by this Section 5(m), (iii) upon order, subpoena, or other process of any court or administrative agency or otherwise required by law,
(iv) upon the request or demand of any regulatory agency or authority having jurisdiction over such party, (v) which has been publicly disclosed without breach of any obligation to the Company, (vi) which has been obtained from any
Person that is not a party hereto or an Affiliate of any such party without any breach of any obligation to the Company, (vii) in connection with the exercise of any remedy, or the resolution of any dispute hereunder, (viii) to the legal
counsel or certified public accountants for any holder of Warrants or Warrant Shares, or (ix) as otherwise expressly contemplated by this Warrant. Notwithstanding the foregoing, the Company shall not provide material, non-public information or
confidential or proprietary information to the Holder without such Holder’s written consent. 
 o) Dispute Resolution. In the
case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares, the Company shall submit the disputed determinations or arithmetic calculations via facsimile within two (2) Business Days of
receipt of the Exercise Notice giving rise to such dispute, as the case may be, to the Holder. If the Holder and the Company are unable to agree upon such determination or calculation of the Exercise Price or the Warrant Shares within three
Business Days of such disputed determination or arithmetic calculation being submitted to the Holder, then the Company shall, within two (2) Business Days submit via facsimile (i) the disputed determination of the Exercise Price to an
independent, reputable investment bank selected by the Company and approved by the Holder or (ii) the disputed arithmetic calculation of the Warrant Shares to the Company’s independent, outside accountant. The Company shall cause at
its expense the investment bank or the accountant, as the case may be, to perform the determinations or calculations and notify the Company and the Holder of the results no later than ten Business Days from the time it receives the disputed
determinations or 

  
 7. 

 
calculations. Such investment bank’s or accountant’s determination or calculation, as the case may be, shall be binding upon all parties absent demonstrable error. The
expenses of the investment bank and accountant will be borne by the Company unless the investment bank or accountant determines that the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares by the Holder was
incorrect, in which case the expenses of the investment bank and accountant will be borne by the Holder. 
 p) Headings. The headings
used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant. 

******************** 

(Signature Pages Follow) 

  
 8. 

 IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto
duly authorized as of the date first above indicated. 
  

			
	 SUNESIS PHARMACEUTICALS, INC.

		
	By:	 	  

	Name:	 	
	Title:	 	

 COUNTERSIGNED: 

AMERICAN STOCK TRANSFER & TRUST COMPANY, 

LLC, as Warrant Agent 

			
		
	By:	 	  

	Name:	 	
	Title:	 	

  
 9. 

 NOTICE OF EXERCISE 

TO: SUNESIS PHARMACEUTICALS, INC. 
 (1) The
undersigned hereby elects to purchase             Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of
the exercise price in full, together with all applicable transfer taxes, if any. 
 (2) Payment shall take the form of lawful money of the
United States 
 (3) Please issue a certificate or certificates representing said Warrant Shares in the name of the undersigned or in such
other name as is specified below: 
  

			
		  	  

 The Warrant Shares shall be delivered to the following DWAC Account Number or by physical delivery of a certificate to: 

 

			
		  	  

		
		  	  

		
		  	  

 [SIGNATURE OF HOLDER] 
  

			
	Name of Investing Entity:	 	  

  

			
	 Signature of Authorized Signatory of Investing Entity:
	 	  

  

			
	 Name of Authorized Signatory:
	 	  

  

			
	 Title of Authorized Signatory:
	 	  

  

			
	 Date:
	 	  

  
 10. 

 ASSIGNMENT FORM 

(To assign the foregoing warrant, execute 

this form and supply required information. 

Do not use this form to exercise the warrant.) 

FOR VALUE RECEIVED, [            ] all of or
[            ] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to 
  

							
	  
	 	 	whose address is	  	 	
	  
	 	 	.	  	 	
	  
	 				 	

  

			
	 Dated:
                                    ,
    

  

							
		  	 Holder’s Signature:
	 	  
	 	
		  	 Holder’s Address:
	 	  
	 	
		  		 	  
	 	

 NOTE: The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without
alteration or enlargement or any change whatsoever. 

  
 11.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}]]